Description

Mannosereceptortargetingbymannosylatedliposomeshasbeendemonstratedforavarietyofmannosylatedlipidconjugatesinavarietyofliposomemorphologiesandcompositionsinseveraldifferent invitro and invivo models.Averylargenumberofpublicationsisaboutusingahydrophobicderivativeofmannose(4-aminophenylalpha-D-mannopyranoside)ratherthanusingamannosylatedlipidinClodronateliposomes.Thisismainlyduetothehighcostandcomplexityofsynthesizingandconjugatingmannosetolipid.4-aminophenylalpha-D-mannopyranosideiscommerciallyavailableandfarlessexpensivethansynthesizingmannoseconjugatedlipid.

Whymannose?Mannoseisoneofthecarbohydratecomponentsofmanybacterialandviralcellsurfaces;therefore,theever-efficient,highlyredundantimmunesystemhasevolvedmultiplemechanismsforidentifyingpathogensbasedonmannoserecognition.Theanimalandplantkingdomslikewiseutilizecarbohydraterecognitionsignalingmechanismsincludingmannoseresidues.Manypublicationsevaluateothercarbohydratesastargetingmechanismsforvariouscelltypes,howevermannosetargetingtophagocytesappearstobeoneofthemorespecificmechanismsidentifiedtodate.Mammaliancellsurfaceidentificationmoleculesbasedonmannosebinding,suchastheICAMfamilyofleukocyteadhesionmolecules,targettheSIGNfamilyofmannosereceptorstoaccomplishself-recognition invivo.

Awell-knownandcitedstudybyUmezawa&Eto [1]demonstratesthatliposomescontainingaminophenylmannosideweremostefficientlyincorporatedintothemousebrainacrossthebloodbrainbarrier.TherADIolabeledliposomesbearingaminophenyl-alpha-D-mannopyranosideweremaximallyincorporatedintothemousebrainafter48hours,whereasinthespleenandliver,theseradioactivitiesweremaximumafter12hours.Thestudiesalsoshowedthatliposomesweremostincorporatedwasglialcellsratherthanneuronalcell.Thesubcellularfractionationstudyindicatesthatmannoselabeledliposomesareincorporatedintolysosomesrichfractionbothinliverandbrain.

Therearefivemannosylatedfluorescentcontrolliposomeproducts(m-Fluoroliposome®)form-Clodrosome®(mannosylatedclodronateliposomes).Allfivemannosylatedfluorescentliposomesincorporatealipophilicdyeinsidetheirmembranes.Theyareinsolubleinwater;however,theirfluorescenceiseasilydetectedwhenincorporatedintomembranes.DiI,DiO,DiD,DiRandDiAcoverawiderangeofexcitationandemissionwavelengthsfrom300sto900s.DiIandDiOhavefluorescenceexcitationandemissionmaximaseparatedbyabout65nm,facilitatingtwo-colorlabeling.TheemissionspectrumofDiAisverybroad,allowingittobedetectedasgreen,orange,orevenredfluorescencedependingontheopticalfilterused.DiI,DiO,DiDandDiRbelongtothedialkylcarbocyaninesfamilyofcompounds.Thespectralpropertiesofthedialkylcarbocyaninesarelargelyindependentofthelengthsofthealkylchainsbutareinsteaddeterminedbytheheteroatomsintheterminalringsystemsandthelengthoftheconnectingbridge.Theyhaveextremelyhighextinctioncoefficients,moderatefluorescencequantumyields,andshortexcitedstatelifetimesinlipidenvironments(~1ns).Thefluorescencespectrumofthedyeisshownbelow.

Youcanchoosethem-Fluoroliposome®basedonthetypeofthefluorescentequipmentandfiltersthatyouuseinyourlab.Mannosylatedclodronateliposomescannotbemadefluorescentsimplyduetothepotentialforinaccurateand/oruninterpretabledatabeinggeneratedbylabelledm-Clodrosome®.Formoreinformation,pleaserefertothetechnicalnotesection.

DownloadProductInsertDownloadSafetyDatasheet(SDS)

FormulationInformation

Clodrosome®LiposomalClodronateSUSPension

Fluoroliposome®-DiD

FluorescentDye	Excitation/Emission(nm)	Concentration(mg/ml)	Concentration(mM)
1,1"-Dioctadecyl-3,3,3",3"-Tetramethylindodicarbocyanine,4-ChlorobenzenesulfonateSalt(DiD)	644/665	0.0625	0.065

BufferandLiposomeSize	Specification
Buffer	PhosphateBufferedSaline
pH	7.4
LiposomeSize	1.5-2µm

TechnicalNotes

• Toreachbloodstream-accessIBLe,mannose-receptorpositivecellsoutsidetheliver,asignificantnumberofliposomeswillhavetoescapefirst-passuptakebytheliverandspleen,sothatthetargetcellsareexposedtoahigherconcentrationofmannosylatedliposomesfromtheblood.Onestrategythathasbeenusedtoensurethatliposomesescapetheliverandspleenisknownasreticuloendothelialsystem(RES)blockadeinwhichanimalsarepre-dosedwithasufficientquantityofliposomestotemporarilysaturatethephagocyticcellsoftheblood,liverandspleen,alsoknownasthereticuloendothelialsystem(RES)orthemononuclearphagocytesystem(MPS).Thissufficientquantityisdependentupontheliposometypeandcompositionaswellasthespeciesbeingdosed;thepre-dosedliposomesdonotnecessarilyneedtobethesametypeorcompositionasthetherapeuticordiagnosticliposomesavoidingtheRES.Soonafterthispre-doseisclearedfromthebloodstream(usuallywithinacoupleofhours),theliposomesofinterestaredosed.SincetheRESisinvolvedindigestingthepreviousdoseofliposomes,thesubsequentlydosedliposomeswillremaininthecirculationmuchlongerthusbemuchmorelikelytobindtotheirtargetsiteoutsidetheRESincludingthosephagocyticcellswhichareaccessible,butarenotusuallyexposedtoahigherconcentrationofliposomes.
• WhileRESblockadeisusuallythoughtofassaturatingphagocyticcells,ithasbeenshownthatopsonin-bindingbyliposomesisasaturablephenomenon.Therefore,partofRESblockademayinvolveserumdepletionofcomplementandotheropsoninsknowntocoatliposomes.Inthecurrentapplication,removalorreductionintheconcentrationofsolublemannose-receptorsmayfurtherincreasetheprobABIlityofamannosylatedliposomebeingabletointeractwithmannosereceptorsonthetargetcell.Therefore,ifthegoalistodepleteatargetsubsetofmannose-receptor+cellswhichmaynotnormallybeexposedtoasubstantialnumberofmannosylatedliposomes,pre-dosingwithmannosylatedclodronateliposomes,inordertobothsaturatetheblood,liverandspleenphagocytesandreducetheconcentrationofopsoninsincludingsolublemannosereceptors,shouldincreasethenumberofsubsequentlydosedmannosylatedclodronateliposomesavailabletothistargetsubsethypotheticallyresultinginincreaseduptakeanddepletionbythesetargetedcells.
• TheissuewithfluorescentClodrosome®hastodowiththepotentialforinaccurateand/oruninterpretabledatabeinggeneratedbylabelledClodrosome®.WhenClodrosome®inducesmacrophageapoptosis,thefluorescentlipidincorporatedintotheClodrosome®thatisdisruptedandmetabolizedinthephagolysosomewillbedispersedamongtheresidualapoptoticbodieswhicharesubsequentlyphagocytosedbyothermacrophages.Therefore,fluorescentlipidmaybedetectedinphagocyticcellswhichneverphagocytosedClodrosome®especiallywhenFACSorfluoroscopyareutilizedtodetectfluorescentcells(FACS)orfluorescencelevelsinatissuehomogenate(fluoroscopy).Anotherpotentialartifactarisesfromfluorescentlipidremainingintheextracellular“garbage”,whichhasnotyetbeenclearedbyotherphagocytes,generatingahighbackgroundfluorescence.However,experiencedconfocalmicroscopistmaybeabletodifferentiatebetweenthepunctatefluorescenceresultingfromfluorescentintactliposomesversusthemorediffusefluorescencecharacteristicofdisruptedliposomesandsomehavesuccessfullyusedfluorescentclodronateliposomestovisualizethecellularlocationoftheseliposomesbyconfocalmicroscopyinvivo[2].Afurthercomplicatingfactoristhatpublisheddatavarieswidelyastoexactlywhenclodronateliposomesbegintoinduceapoptosisinmacrophages.Mönkönnnen etal.showthatmacrophagedeathismeasurablewithinthefirsthourafterclodronateliposometreatmentonRAW264cellsinvitro[3],whileothershavereportednosignsofmacrophageapoptosisuntilseveralhoursaftertreatmentinvivo.Thevariabilityinthedataislikelyduetodifferentliposomalformulationsofclodronateaswellasthevastlydifferentexperimentalconditions.Therefore,aswithmostBIOLOGicalstudies,especiallythoseinvolvingliposomes,theamountoftimebetweentreatingtheanimalorcellswithclodronateliposomesandtheonsetofapoptosiswillneedtobeestablishedineachexperimentalmodel.IfthenatureoftheresearchdemandsthatClodrosome®betrackedratherthanthecontrol,EncapsulacanprovideDiI-labelledClodrosome®uponrequest,andassumingthattheClodrosome®distributioncandefinitivelybeassessedpriortotheonsetofapoptosis,clearandvaliddataonthebiodistributionoffluorescentClodrosome®shouldbeobtainable.Still,formostpurposes,Fluoroliposome®(fluorescentcontrolliposomes)willprovidetherequireddatawithfarfewerpotentialartifacts.
• Whenmonitoringmonocyteuptakeinvivoinnormalanimals,thecirculatingmonocytesmay“disappear”orshowreducedcountswithinthefirst2hpost-injectionduetomarginationofthemonocytespost-liposomephagocytosis.Thesecellswillre-enterthecirculationwithinafewhours.Sunderkötter etal.demonstratethisphenomenonanddiscussthebehaviorindetail.Alsoconsiderthatcirculatingmonocyteshavealifetimeofabout24hsolabeledmonocyteswillbecontinuallyleavingthecirculation,eveninnormalanimals,duetoagingofthemonocytes[4].
• WhenanimalsorcellsaretreatedwithClodrosome®,phagocyticcellsrecognizetheliposomesasinvadingforeignparticlesandproceedtoremovetheliposomesfromthelocaltissueorserumviaphagocytosis.Theliposomesthenreleaseclodronateintothecytosolresultingincelldeath.Unencapsulatedclodronatecannotcrossthecellmembranetoinitiatecelldeath.
• Encapsome®controlliposomesarerecognizedandphagocytosedbythesamemechanismasClodrosome®.Sincethecontrolliposomesdonotcontainclodronate,thephagocyticcellsarenotkilled.However,phagocytesdorespondtotheingestionofthecontrolliposomesbycytokinesecretion,temporarysuspensionofphagocyticactivityandotherresponsesdescribedintheliterature.
• Theproductmustberemovedfromthevialusingsteriletechnique.Donotuseifsterilityiscompromised.Thisisparticularlyimportantifasinglevialisaccessedmultipletimesoverseveralweeks.Theproductshouldnotbeusedmorethan60daysafterreceipt,evenifunopened.
• Liposomesmaysettlewhenleftundisturbedformorethanafewhours.Immediatelypriortouse,inordertoensureahomogeneousliposomesuspension,slowlyinvertthevialseveraltimesuntilthesuspensionappearshomogeneousbyvisualinspection.Vigorousorerraticshakingwillnotdamagetheliposomesbutmayinducefoamingandbubbleformationmakingitmoredifficulttoaccuratelymeasurethedesireddosage.
• Ifthepersonnelperformingintravenousinjectionsarenotexperiencedinorfamiliarwith,precautionsforinjectinglargervolumes(~10%animalweightinml),viscousliquidsorparticulatesuspensions,considerhavingextraanimalsavailableincaseseriousinjection-relatedadverseeventsoccur.Dosecontrolanimalsfirsttobecomefamiliarwithlargevolumeinjections.
• WithinhoursaftersystemicadmiNISTrationofClodrosome®,animalsbegintoloseimportantcomponentsoftheirimmunesystem.Standardanimalhandlingandhousingprotocolsarenotsuitableforimmunocompromisedanimals.Evenwhensuchprecautionsaretaken,monitorthegeneralhealthofeachanimalforopportunisticinfectionsunrelatedtotheexperimentalprotocol.Thereisnoinherenttoxicitytotheproductattherecommendeddoselevels.
• Whendosingintravenously,usestandardprecautionsfordosinglargervolumestoanimalsincludingthefollowing:a)warmproducttoroomtemperaturepriortodosing;b)ensurethatallairbubblesareremovedfromthesyringepriortodosing.Intravenousinjectionofairbubblesmayresultinairemboliwhichcankillorseriouslyinjureanimals;c)injectproductataslow,steadyrateofnomorethan1ml/min;d)decreaseinfusionrateifanimalsdisplayanyatypicalreactionssuchasunusualagitation.
• Infusion-relatedadversereactionsusuallyinvolvetheanimalgaspingforairorotherseizure-likemovements.Animalsoftenrecoverwithnoapparentpermanentinjury,butanypotentialeffectsonexperimentalresultsmustbeassessedbytheresearcher.
• Liposomesshouldbekeptat4°CandNEVERbefrozen.

Dosage

Appearance

m-Clodrosome®isawhitemilkysuspension,andm-Fluoroliposome®-DiDisablueliquidsuspension,bothmadeoflargemicrosizemultilamellarliposomes.Duetotheirlargesize,someliposomesmightsettletothebottomofthevial.Ifleftsittingidleintherefrigerator,m-Fluoroliposome®-DiDwillphaseseparateandformpelletsinthebottomofthevial,leavingaclearsolutionontop.m-Clodrosome®mightdothesameonlynotasseverely.Therefore,bothshouldbeshakentoformahomogeneoussolutionpriortouse.

EducationalVideos

Ordering/ShippingInformation

• Allliposomebasedformulationsareshippedonblueiceat4°Cininsulatedpackagesusingovernightshippingorinternationalexpressshipping.
• LiposomesshouldNEVERbefrozen.Icecrystalsthatforminthelipidmembranecanrupturethemembrane,changethesizeoftheliposomesandcausetheencapsulateddrugtoleakout.Liposomesinliquidformshouldalwaysbekeptintherefrigerator.
• ClientswhoorderfromoutsideoftheUnitedStatesofAmericaareresponsiblefortheirgovernmentimporttaxesandcustomspaperwork.EncapsulaNanoSciencesisNOTresponsibleforimportationfeestocountriesoutsideoftheUnitedStatesofAmerica.
• WestronglyencouragetheclientsinJapan,Korea,TaiwanandChinatoorderviaadistributor.Toughcustomsclearanceregulationsinthesecountrieswillcausedelayincustomclearanceoftheseperishableformulationsifordereddirectlythroughus.Distributorscaneasilyclearthepackagesfromcustoms.Toseethelistofthedistributorsclickhere.
• ClientsorderingfromuniversitiesandresearchinstitutesinAustraliashouldkeepinmindthattheliposomeformulationsaremadefromsyntheticmaterialandtheformulationsdonotrequirea“permittoimportquarantinematerial”.LiposomesareNOTbiologicalproducts.
• Ifyouwouldlikeyourinstitute’sFedExorDHLaccounttobechargedforshipping,thenpleaseprovidetheaccountnumberatthetimeofordering.
• EncapsulaNanoScienceshasnocontroloverdelaysduetoinclementweatherorcustomsclearancedelays.YouwillreceiveaFedExorDHLtrackingnumberonceyourorderisconfirmed.ContactFedExorDHLinadvanceandmakesurethatthepaperworkforcustomsisdoneontime. AllsubsequentshippinginquiriesshouldbedirectedtoFederalExpressorDHL.

StorageandShelfLife

Storage

m-Clodrosome®andm-Fluoroliposome®shouldalwaysbestoredatinthedarkat4°C,exceptwhenbroughttoroomtemperatureforbriefperiodspriortoanimaldosing.DONOTFREEZE.Ifthesuspensionisfrozen,clodronatecanbereleasedfromtheliposomesthuslimitingitseffectivenessindepletingmacrophages.ENSisnotresponsibleforresultsgeneratedbyfrozenproduct.

ShelfLife

m-Clodrosome®andFluoroliposome®aremadeondailybasis.Thebatchthatisshippedismanufacturedonthesameday.Itisadvisedtousetheproductswithin60daysofthemanufacturingdate.

Referencesandbackgroundreading

1.UmezawaFA,EtoY.Liposometargetingtomousebrain:mannoseasarecognitionMarker.Biochemicalandbiophysicalresearchcommunications.1988Jun30;153(3):1038-44.

2.PolflietMM,GoedePH,vanKesteren-HendrikxEM,vanRooijenN,DijkstraCD,vandenBergTK.Amethodfortheselectivedepletionofperivascularandmeningealmacrophagesinthecentralnervoussystem.J.Neuroimmunol.2001Jun1;116(2):188–95.

3.MönkkönenJ,LiukkonenJ,TaskinenM,HeathTD,UrttiA.Studiesonliposomeformulationsforintra-articulardeliveryofclodronate.JournalofControlledRelease.1995Aug;35(2–3):145–54.

4.SunderkötterC,NikolicT,DillonMJ,vanRooijenN,StehlingM,DrevetsDA,LeenenP.SubpopulationsofMouseBloodMonocytesDifferinMaturationStageandInflammatoryResponse.JImmunol.2004Apr1;172(7):4410–7.

5.NagaiH,KuwahiraI,SchwenkeDO,TsuchimochiH,NaraA,OguraS,SonobeT,InagakiT,FujiiY,YamaguchiR,WingenfeldL.Pulmonarymacrophagesattenuatehypoxicpulmonaryvasoconstrictionviaβ3AR/iNOSpathwayinratsexposedtochronicintermittenthypoxia.PLoSOne.2015Jul1;10(7):e0131923.

6.ZhuY,SoderblomC,KrishnanV,AshbaughJ,BetheaJR,LeeJK.Hematogenousmacrophagedepletionreducesthefibroticscarandincreasesaxonalgrowthafterspinalcordinjury.Neurobiologyofdisease.2015Feb28;74:114-25.

7.YunMH,DavaapilH,BrockesJP.Recurrentturnoverofsenescentcellsduringregenerationofacomplexstructure.Elife.2015;4:e05505.

8.ArwertEN,HarneyAS,EntenbergD,WangY,SahaiE,PollardJW,CondeelisJS.AUnidirectionalTransitionfromMigratorytoPerivascularMacrophageIsRequiredforTumorCellIntravasation.Cellreports.2018May1;23(5):1239-48.

9.ItoT,IshigamiM,MatsushitaY,HirataM,MatsubaraK,IshikawaT,HibiH,UedaM,HirookaY,GotoH,YamamotoA.SecretedEctodomainofSIGLEC-9andMCP-1SynergisticallyImproveAcuteLiverFailureinRatsbyAlteringMacrophagePolarity.Scientificreports.2017Mar8;7:44043.

10.MironVE,BoydA,ZhaoJW,YuenTJ,RuckhJM,ShadrachJL,vanWijngaardenP,WagersAJ,WilliamsA,FranklinRJ.M2microgliaandmacrophagesdriveoligodendrocytedifferentiationduringCNSremyelination.Natureneuroscience.2013Sep;16(9):1211.

11.AndreouK,SarmientoSotoM,AllenD,EconomopoulosV,deBernardiA,LarkinJ,SibsonNR.Anti-InflammatoryMicroglia/MacrophagesasaPotentialTherapeuticTargetinBrainMetastasis.Frontiersinoncology.2017;7:251.

12.AlishekevitzD,Gingis-VelitskiS,Kaidar-PersonO,Gutter-KaponL,SchererSD,RavivZ,MerquiolE,Ben-NunY,MillerV,Rachman-TzemahC,TimanerM.Macrophage-inducedlymphangiogenesisandmetastasisfollowingpaclitaxelchemotherapyisregulatedbyVEGFR3.Cellreports.2016Oct25;17(5):1344-56.

13.OhSH,KimHN,ParkHJ,ShinJY,BaeEJ,SunwooMK,LeeSJ,LeePH.Mesenchymalstemcellsinhibittransmissionofα-synucleinbymodulatingclathrin-mediatedendocytosisinaParkinsonianmodel.Cellreports.2016Feb2;14(4):835-49.

14.KanoF,MatsubaraK,UedaM,HibiH,YamamotoA.SecretedEctodomainofSialicAcid‐BindingIg‐LikeLectin‐9andMonocyteChemoattractantProtein‐1SynergisticallyRegenerateTransectedRatPeripheralNervesbyAlteringMacrophagePolarity.STEMCELLS.2017Mar1;35(3):641-53.